BioMark Diagnostics Inc.
BMKDF
$0.254
$0.0010.40%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.71% | -7.80% | -9.84% | -10.51% | -5.41% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.71% | -7.80% | -9.84% | -10.51% | -5.41% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.71% | -7.80% | -9.84% | -10.51% | -5.41% |
| SG&A Expenses | -47.85% | 27.87% | -10.12% | 15.20% | 95.28% |
| Depreciation & Amortization | 72.04% | 111.36% | -42.74% | -36.89% | -44.69% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.05% | 18.16% | -29.41% | 32.68% | 34.21% |
| Operating Income | 36.34% | -20.39% | 31.34% | -37.12% | -38.03% |
| Income Before Tax | 33.98% | -1.31% | 20.00% | -155.77% | -46.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 33.98% | -1.31% | 20.00% | -155.77% | -46.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.98% | -1.31% | 20.00% | -155.77% | -46.09% |
| EBIT | 36.34% | -20.39% | 31.34% | -37.12% | -38.03% |
| EBITDA | 36.63% | -20.54% | 31.76% | -37.33% | -38.34% |
| EPS Basic | 42.00% | 17.65% | 91.43% | -131.58% | -35.14% |
| Normalized Basic EPS | 41.94% | 19.05% | 90.91% | -133.33% | -34.78% |
| EPS Diluted | 42.00% | 17.65% | 91.43% | -131.58% | -35.14% |
| Normalized Diluted EPS | 41.94% | 19.05% | 90.91% | -133.33% | -34.78% |
| Average Basic Shares Outstanding | 15.63% | 23.29% | 938.55% | 9.13% | 9.13% |
| Average Diluted Shares Outstanding | 15.63% | 23.29% | 938.55% | 9.13% | 9.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |